Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.


The Company is focused on well-understood diseases that are poorly served by available therapies or have no approved therapies. Acasti is initially targeting three underserved orphan diseases - Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN) – all with sizable patient populations and significant market opportunity. 


The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents.

Read more


A novel intravenous infusion of nimodipine being developed to treat Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which a ruptured aneurysm causes bleeding to occur over the surface of the brain in the subarachnoid space between the brain and skull.


A novel oral mucosal spray formulation of betamethasone being developed to treat the symptoms of Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists.


A novel bio-adhesive, film forming topical spray formulation of bupivacaine being developed to treat Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.